eHealth Initiative

ehidc.org

eHealth Initiative and Foundation (eHI) is a Washington DC-based, independent, non-profit organization whose mission is to drive improvements in the quality, safety, and efficiency of healthcare through information technology. eHI is a multi-stakeholder collaborative, convening executives from every group in healthcare, to discuss, identify, and share best practices that transform the delivery of healthcare. Working with its membership, eHI advocates for the use of health IT that is practical, sustainable, and addresses stakeholder needs, particularly those of patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PATIENT SUCCESSFULLY TREATED FOR CORONAVIRUS IN THE US

Pharmafile: Home | February 11, 2020

news image

The Ebola drug Remdesivir, made by Gilead Sciences, was given to an American who is 35 years old. The doctors reported that on 26 January his condition seemed to improve within a day, and by 30 January it had resolved most of the symptoms except a cough. However, Gilead feel this is not conclusive proof that it's an effective treatment. Ryan McKeel, a spokesperson for the company, said: “We do not have an appropriately robust understanding of the effect of this drug to warrant broad us...

Read More

GLAXOSMITHKLINE JUMPS INTO MYELOMA WITH 'HOMEMADE' ANTI-BCMA DRUG BLENREP

GlaxoSmithKline | August 07, 2020

news image

Back in 2015, GlaxoSmithKline traded away its marketed cancer assets and began building its oncology pipeline “pretty aggressively,” as Axel Hoos, the company’s SVP of Oncology R&D, puts it. Those efforts have finally paid off with a new approval. But just how much remains to be seen, with analysts expecting "limited adoption" for the company's newcomer thanks to a Black Box warning for eye toxicity. The FDA late Wednesday green-lighted Blenrep—formerly ...

Read More

Business Insights

AGILENT ANNOUNCES THE INNOVATIVE SEAHORSE XF PRO ANALYZER

Agilent Technologies Inc. | January 25, 2022

news image

Agilent Technologies Inc. announced the release of the Agilent Seahorse XF Pro Analyzer, featuring new pharma-oriented workflow solutions incorporating advanced experimental design and analysis tools. With enhanced performance, more robust and efficient workflows, and an optimized user experience, the XF Pro enables operators at any skill level to access the most advanced cellular metabolism analysis technology for understanding cellular fate, fitness, and function. Preclinical th...

Read More

OBI PHARMA ANNOUNCES OBI-999 PRESENTATION AT 2020 WORLD ADC DIGITAL MEETING

OBI Pharma | September 14, 2020

news image

OBI Pharma, Inc, a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announced a scientific presentation will be held for OBI-999 (anti-Globo H targeted ADC) at the World ADC Digital Scientific meeting on Sept 16, 2020. The scientific presentation titled, "A Novel Globo H-targeting Antibody-drug Conjugate: OBI 999" with a follow-up live discussion and question session will be l...

Read More
news image

PATIENT SUCCESSFULLY TREATED FOR CORONAVIRUS IN THE US

Pharmafile: Home | February 11, 2020

The Ebola drug Remdesivir, made by Gilead Sciences, was given to an American who is 35 years old. The doctors reported that on 26 January his condition seemed to improve within a day, and by 30 January it had resolved most of the symptoms except a cough. However, Gilead feel this is not conclusive proof that it's an effective treatment. Ryan McKeel, a spokesperson for the company, said: “We do not have an appropriately robust understanding of the effect of this drug to warrant broad us...

Read More
news image

GLAXOSMITHKLINE JUMPS INTO MYELOMA WITH 'HOMEMADE' ANTI-BCMA DRUG BLENREP

GlaxoSmithKline | August 07, 2020

Back in 2015, GlaxoSmithKline traded away its marketed cancer assets and began building its oncology pipeline “pretty aggressively,” as Axel Hoos, the company’s SVP of Oncology R&D, puts it. Those efforts have finally paid off with a new approval. But just how much remains to be seen, with analysts expecting "limited adoption" for the company's newcomer thanks to a Black Box warning for eye toxicity. The FDA late Wednesday green-lighted Blenrep—formerly ...

Read More
news image

Business Insights

AGILENT ANNOUNCES THE INNOVATIVE SEAHORSE XF PRO ANALYZER

Agilent Technologies Inc. | January 25, 2022

Agilent Technologies Inc. announced the release of the Agilent Seahorse XF Pro Analyzer, featuring new pharma-oriented workflow solutions incorporating advanced experimental design and analysis tools. With enhanced performance, more robust and efficient workflows, and an optimized user experience, the XF Pro enables operators at any skill level to access the most advanced cellular metabolism analysis technology for understanding cellular fate, fitness, and function. Preclinical th...

Read More
news image

OBI PHARMA ANNOUNCES OBI-999 PRESENTATION AT 2020 WORLD ADC DIGITAL MEETING

OBI Pharma | September 14, 2020

OBI Pharma, Inc, a leader in Glycosphingolipid Immuno-Oncology therapeutics targeting the Globo Series antigens (Globo H and SSEA-4) and chemotherapeutics targeting AKR1C3, today announced a scientific presentation will be held for OBI-999 (anti-Globo H targeted ADC) at the World ADC Digital Scientific meeting on Sept 16, 2020. The scientific presentation titled, "A Novel Globo H-targeting Antibody-drug Conjugate: OBI 999" with a follow-up live discussion and question session will be l...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us